TRDA - Entrada Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.00
DETAILS
HIGH:
$21.00
LOW:
$10.00
MEDIAN:
$20.00
CONSENSUS:
$17.00
UPSIDE:
159.15%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Revenue | 25.4 | 210.8 | 129.0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.1 | 0 | 0 | 0 | 0 | 0.3 | 0.1 |
| Gross Profit | 21.3 | 210.8 | 129.0 | 0 | 0 | (0.3) | (0.1) |
| Operating Expenses | |||||||
| R&D Expenses | 142.3 | 125.3 | 99.9 | 66.6 | 35.9 | 21.1 | 8.2 |
| SG&A Expenses | 41.0 | 38.5 | 32.3 | 30.6 | 15.2 | 5.2 | 3.6 |
| Other Expenses | (6.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 177.3 | 163.8 | 132.2 | 97.2 | 51.1 | 26.3 | 11.8 |
| Operating Income | |||||||
| Operating Income | (156.0) | 47.0 | (3.2) | (97.2) | (51.1) | (26.7) | (11.8) |
| Interest Expense | 0 | 0 | 0 | 2.6 | 0 | 0 | 0 |
| Interest Income | 0 | 19.5 | 15.2 | 2.6 | 0 | 0 | 0 |
| Profitability | |||||||
| EBITDA | (142.4) | 50.8 | (0.3) | (95.4) | (50.0) | (26.2) | (11.7) |
| EBIT | (142.8) | 47.0 | (3.2) | (97.2) | (51.1) | (26.5) | (11.8) |
| Income Before Tax | (142.8) | 66.5 | 12.1 | (94.6) | (51.2) | (26.5) | (5.1) |
| Income Tax Expense | 0.9 | 0.9 | 18.7 | 0 | 0 | 0 | 0 |
| Net Income | (143.8) | 65.6 | (6.7) | (94.6) | (51.2) | (26.5) | (4.6) |
| Per Share Data | |||||||
| EPS (Basic) | -3.47 | 1.76 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| EPS (Diluted) | -3.47 | 1.68 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Shares Outstanding | 41.4 | 37.3 | 33.1 | 31.3 | 31.2 | 31.2 | 1.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Current Assets | |||||||
| Cash & Cash Equivalents | 90.4 | 101.2 | 67.6 | 45.2 | 291.1 | 39.0 | 16.8 |
| Short-Term Investments | 205.3 | 318.8 | 284.4 | 143.6 | 0 | 0 | 0 |
| Net Receivables | 0 | 3.7 | 5.9 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 10.6 | 16.4 | 11.9 | 21.2 | 0 | 0 | 0 |
| Total Current Assets | 306.3 | 440.0 | 369.8 | 209.9 | 298.7 | 39.9 | 17.4 |
| Non-Current Assets | |||||||
| Property, Plant & Equipment | 67.8 | 82.0 | 92.7 | 33.0 | 6.3 | 3.0 | 0.8 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.4 | 4.2 | 6.7 | 9.2 | 0.9 | 0.5 | 0 |
| Total Non-Current Assets | 71.1 | 86.3 | 99.4 | 42.2 | 7.1 | 3.6 | 0.8 |
| Total Assets | 377.4 | 526.3 | 469.2 | 252.1 | 305.8 | 43.5 | 18.2 |
| Current Liabilities | |||||||
| Account Payables | 2.3 | 4.3 | 3.3 | 6.0 | 0.7 | 1.6 | 0.7 |
| Short-Term Debt | 4.1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0.3 | 13.7 | 132.3 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 17.7 | 8.4 | 7.7 | 5.5 | 4.6 | 1.6 | 0.9 |
| Total Current Liabilities | 24.5 | 39.5 | 158.8 | 22.0 | 6.7 | 3.4 | 1.9 |
| Non-Current Liabilities | |||||||
| Long-Term Debt | 46.8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0.4 | 81.7 | 31.8 |
| Total Non-Current Liabilities | 46.8 | 58.2 | 68.0 | 17.5 | 0.4 | 81.7 | 31.8 |
| Total Liabilities | 71.2 | 97.6 | 226.8 | 39.5 | 7.1 | 85.0 | 33.8 |
| Stockholders' Equity | |||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 |
| Retained Earnings | (273.1) | (129.3) | (195.0) | (188.3) | (93.7) | (42.5) | (16.0) |
| Accumulated Other Comprehensive Income | 0.7 | (0.0) | 0.2 | (2.1) | 0 | 0 | 0 |
| Total Stockholders' Equity | 306.1 | 428.7 | 242.4 | 212.6 | 298.7 | (41.5) | (15.5) |
| Total Liabilities & Equity | 377.4 | 526.3 | 469.2 | 252.1 | 305.8 | 43.5 | 18.2 |
| Debt Metrics | |||||||
| Total Debt | 50.9 | 59.2 | 68.2 | 25.9 | 0 | 0 | 0 |
| Net Debt | (39.5) | (42.0) | 0.6 | (19.2) | (291.1) | (39.0) | (16.8) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | (143.8) | 65.6 | (6.7) | (94.6) | (51.2) | (26.5) | (5.1) |
| Depreciation & Amortization | 0.4 | 3.8 | 2.8 | 1.9 | 1.1 | 0.3 | 0.1 |
| Stock-Based Compensation | 19.6 | 17.9 | 13.1 | 9.9 | 2.5 | 0.3 | 0.3 |
| Change in Working Capital | (4.8) | (118.9) | 136.3 | (11.1) | (3.4) | 0.3 | 0.2 |
| Other Non-Cash Items | 0 | (10.0) | (5.8) | 0.2 | 0.1 | 0.0 | (6.3) |
| Operating Cash Flow | (128.5) | (41.6) | 139.8 | (93.8) | (50.9) | (25.6) | (10.8) |
| Investing Activities | |||||||
| Capital Expenditure | (1.0) | (3.2) | (5.6) | (2.9) | (4.6) | (2.3) | (0.6) |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (141.6) | (437.7) | (407.2) | (222.0) | 0 | 0 | 0 |
| Sales/Maturities of Investments | 259.5 | 413.1 | 274.4 | 76.2 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 116.8 | (27.8) | (138.4) | (148.7) | (4.6) | (2.3) | (0.6) |
| Financing Activities | |||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 3.4 | 1.6 | 0 | 0.9 | 0.2 | 0 |
| Financing Cash Flow | 0.9 | 103.0 | 21.0 | 0.5 | 307.5 | 50.1 | 0.0 |
| Cash Position | |||||||
| Net Change in Cash | (10.8) | 33.6 | 22.4 | (245.9) | 252.0 | 22.2 | 16.8 |
| Cash at Beginning | 105.2 | 71.6 | 49.1 | 291.1 | 39.0 | 16.8 | 0 |
| Cash at End | 94.3 | 105.2 | 71.6 | 45.2 | 291.1 | 39.0 | 16.8 |
| Free Cash Flow | (129.6) | (44.7) | 134.2 | (96.7) | (55.4) | (27.9) | (11.4) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 25.4 | 210.8 | 129.0 | 0 | 0 | 0 | 0 |
| Gross Profit | 21.3 | 210.8 | 129.0 | 0 | 0 | (0.3) | (0.1) |
| Operating Income | (156.0) | 47.0 | (3.2) | (97.2) | (51.1) | (26.7) | (11.8) |
| Net Income | (143.8) | 65.6 | (6.7) | (94.6) | (51.2) | (26.5) | (4.6) |
| EPS (Diluted) | -3.47 | 1.68 | -0.20 | -2.79 | -1.60 | -0.84 | -4.44 |
| Balance Sheet | |||||||
| Cash & Equivalents | 90.4 | 101.2 | 67.6 | 45.2 | 291.1 | 39.0 | 16.8 |
| Total Assets | 377.4 | 526.3 | 469.2 | 252.1 | 305.8 | 43.5 | 18.2 |
| Total Debt | 50.9 | 59.2 | 68.2 | 25.9 | 0 | 0 | 0 |
| Stockholders' Equity | 306.1 | 428.7 | 242.4 | 212.6 | 298.7 | (41.5) | (15.5) |
| Cash Flow | |||||||
| Operating Cash Flow | (128.5) | (41.6) | 139.8 | (93.8) | (50.9) | (25.6) | (10.8) |
| Capital Expenditure | (1.0) | (3.2) | (5.6) | (2.9) | (4.6) | (2.3) | (0.6) |
| Free Cash Flow | (129.6) | (44.7) | 134.2 | (96.7) | (55.4) | (27.9) | (11.4) |